Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Will Observe Project Orbis In Effort To Increase Collaboration

Executive Summary

The goal is for EMA officials to better understand the process, but becoming an official member still may prove difficult because of the EMA regulatory scheme.

You may also be interested in...

EMA To Become Observer Of FDA’s Project Orbis Early This Year

The European medicines regulator has put in place the necessary arrangements to begin watching the Project Orbis process imminently but has maintained its stance that the initiative focuses only on the “magic moment” of a drug approval.

Complex Generic Sponsors Not Using US FDA-EMA Parallel Scientific Advice Program

After nearly two years, the program has received only two requests, driving FDA officials to try to boost interest.

EMA Picks Antibiotic Combo & RSV Vaccine For New International Parallel Review Framework

The first products to be selected for review under the European Medicines Agency’s newly extended OPEN framework for collaboratively assessing marketing applications with non-EU authorities are from Pfizer/AbbVie and Moderna.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts